The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed RevMed’s first-in-class pancreatic cancer therapy, according to a regulatory update. The recommendation follows earlier FDA approvals for the company’s RAS(ON) inhibitor strategy and Lilly’s obesity drug Foundayo (orforglipron), underscoring a busy period for targeted oncology and metabolic pipelines tied to pancreatic disease. While the CHMP endorsement is not an automatic authorization, it typically sets up the next step toward an EU decision and can influence access pathways for clinicians awaiting new options in a high-need setting. For developers and investors, the key signal is that the agency’s review continues to reward mechanism-driven programs in difficult-to-treat solid tumors—potentially reshaping how sponsors plan evidence packages and sequencing across regulators.